Debt-to-equity of Monte Rosa Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Monte Rosa Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Monte Rosa Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 63%, a 2.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Monte Rosa Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 63% +1.8% +2.9% 30 Sep 2025
Q2 2025 55% -2.4% -4.2% 30 Jun 2025
Q1 2025 61% +9.8% +19% 31 Mar 2025
Q4 2024 69% +30% +77% 31 Dec 2024
Q3 2024 61% +32% +109% 30 Sep 2024
Q2 2024 57% +31% +119% 30 Jun 2024
Q1 2024 51% +27% +112% 31 Mar 2024
Q4 2023 39% +21% +112% 31 Dec 2023
Q3 2023 29% +16% +121% 30 Sep 2023
Q2 2023 26% +18% +203% 30 Jun 2023
Q1 2023 24% +19% +409% 31 Mar 2023
Q4 2022 19% 31 Dec 2022
Q3 2022 13% 30 Sep 2022
Q2 2022 8.7% 30 Jun 2022
Q1 2022 4.7% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.